Proxy Votes Now

Home › Funds › John Hancock › Capital Appreciation Value Trust

Capital Appreciation Value Trust (JAFPX) proxy voting record 2025-2026

Fund family: John Hancock · Filed by JOHN HANCOCK VARIABLE INSURANCE TRUST (CIK 756913) · SEC series S000021933

Share classes and tickers: JAFPX (C000063027), JAFQX (C000063028), JAFRX (C000063026)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 610 with, 68 against, 9 abstentions (not counted as with management); 1 items carried no recommendation. Shareholder proposals: 9 FOR, 60 AGAINST, 1 abstained, by the filing’s own vote-source field.

Compared with John Hancock as a whole

The same two figures as John Hancock’s manager page (290,519 ballot items across 99 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsJohn HancockItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)95.7%60190.1%242,172
Backed environmental and social shareholder proposals at US companiesn/a4413.4%1,935

Where this fund voted differently from most John Hancock funds

Each ballot item this fund voted is set against the votes of the other John Hancock funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted differently from most John Hancock funds on 34 items (5.3% of the 647 items where a comparison was possible).

The most lopsided family majorities first, then the largest companies, then shareholder proposals.
CompanyMeetingItemThis fundMost John Hancock fundsMgmtResult
APPLE INC.2026-02-24The election to Apple's Board of Directors of the eight nominees named in the Proxy Statement Andrea JungAgainstFOR — 27 of 27 John Hancock fundsAgainst—
ARISTA NETWORKS, INC.2026-05-29Approval, on an advisory basis, of the compensation of our named executive officers.ForAGAINST — 10 of 11 John Hancock fundsForApproved, 60.4% support
ALNYLAM PHARMACEUTICALS, INC.2026-05-20To elect the following nominees as Class I directors of Alnylam: Stuart A. ArbuckleAgainstFOR — 6 of 6 John Hancock fundsAgainstElected, 95.8% support
META PLATFORMS, INC.2026-05-27DIRECTOR: Robert M. KimmittAbstainFOR — 19 of 24 John Hancock fundsAgainst—
S&P GLOBAL INC.2026-05-20Shareholder Vote on a shareholder proposal to reduce the stock ownership threshold for calling a special shareholder meeting;AgainstFOR — 9 of 10 John Hancock fundsForFailed (calculated), 40.8% support
REVVITY, INC.2026-04-28Shareholder To approve the shareholder proposal regarding Executives to Retain Significant Stock.AgainstFOR — 9 of 10 John Hancock fundsForFailed (calculated), 23.1% support
BROADCOM INC2026-04-20Advisory vote to approve the named executive officer compensation.ForAGAINST — 15 of 19 John Hancock fundsForApproved, 66.4% support
VISA INC.2026-01-27To elect the eleven director nominees named in the proxy statement. William ReadyAgainstFOR — 12 of 15 John Hancock fundsAgainst—
DOORDASH, INC.2026-06-10The election of the following director nominee(s): Milan KovacAgainstFOR — 9 of 11 John Hancock fundsAgainstElected, 96.9% support
YUM! BRANDS, INC.2026-05-14Shareholder Shareholder Proposal to Reduce the Percentage of Shares Required to Call a Special Meeting.AgainstFOR — 6 of 7 John Hancock fundsForNot approved, 37.7% support
CENTERPOINT ENERGY, INC.2026-04-16Approve CenterPoint Energy, Inc.'s Amended and Restated Certificate of Formation to provide for limited officer exculpation and make certain other immaterial updates.ForAGAINST — 8 of 10 John Hancock fundsForApproved, 60.7% support
CONOCOPHILLIPS2026-05-12Shareholder Stockholder Proposal - Independent Board Chairman.AgainstFOR — 9 of 12 John Hancock fundsForNot approved, 28.0% support
CYTOKINETICS, INCORPORATED2026-05-27Election of Class I Directors for terms expiring in 2029. Wendell Wierenga, Ph.D.WithholdFOR — 7 of 9 John Hancock fundsAgainst—
ALNYLAM PHARMACEUTICALS, INC.2026-05-20To elect the following nominees as Class I directors of Alnylam: Elliott Sigal, M.D., Ph.D.AgainstFOR — 5 of 6 John Hancock fundsAgainstElected, 89.3% support
AURORA INNOVATION, INC.2026-05-21Election of Directors Gloria BoylandForWITHHOLD — 3 of 3 John Hancock fundsFor—
VISA INC.2026-01-27Shareholder Shareholder proposal on shareholder right to act by written consent.AgainstFOR — 10 of 15 John Hancock fundsForNot approved, 33.0% support
NETFLIX, INC.2026-06-04Shareholder Stockholder proposal entitled, "Proposal 4 - Shareholder Right to Act by Written Consent," if properly presented at the meeting.AgainstFOR — 7 of 10 John Hancock fundsForNot approved, 44.6% support
ALPHABET INC.2026-06-05Advisory vote to approve compensation awarded to named executive officersForAGAINST — 16 of 29 John Hancock fundsForApproved, 81.1% support
MASTERCARD INCORPORATED2026-06-16Shareholder Consideration of a stockholder proposal regarding shareholder right to act by written consentAgainstFOR — 8 of 13 John Hancock fundsForNot approved, 30.1% support
VAXCYTE, INC.2026-06-15DIRECTOR: Halley Gilbert, J.D.ForABSTAIN — 5 of 8 John Hancock fundsFor—
VAXCYTE, INC.2026-06-15DIRECTOR: Olivier Brandicourt MDForABSTAIN — 5 of 8 John Hancock fundsFor—
KYMERA THERAPEUTICS, INC.2026-06-24DIRECTOR: Bruce Booth, D.Phil.ForABSTAIN — 4 of 6 John Hancock fundsFor—
KYMERA THERAPEUTICS, INC.2026-06-24DIRECTOR: Elena Ridloff, CFAForABSTAIN — 4 of 6 John Hancock fundsFor—
KYMERA THERAPEUTICS, INC.2026-06-24DIRECTOR: John Maraganore, Ph.D.ForABSTAIN — 4 of 6 John Hancock fundsFor—
KYMERA THERAPEUTICS, INC.2026-06-24DIRECTOR: Nello Mainolfi, Ph.D.ForABSTAIN — 4 of 6 John Hancock fundsFor—
Show all 34
Items 26 to 34.
CompanyMeetingItemThis fundMost John Hancock fundsMgmtResult
ADVANCED MICRO DEVICES, INC.2026-05-13Shareholder Stockholder proposal requesting changes to the stockholder right to call a special meeting.AgainstFOR — 5 of 9 John Hancock fundsForNot approved, 37.5% support
CG ONCOLOGY, INC.2026-06-04To elect the Board's two nominees for Class II director named as nominees to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal. Victor Tong, Jr.ForWITHHOLD — 3 of 5 John Hancock fundsFor—
ERASCA, INC.2026-06-26To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified Alexander W. CasdinForWITHHOLD — 3 of 5 John Hancock fundsFor—
ERASCA, INC.2026-06-26To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified Julie Hambleton, M.D.ForWITHHOLD — 3 of 5 John Hancock fundsFor—
ERASCA, INC.2026-06-26To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified Michael D. Varney, Ph.D.ForWITHHOLD — 3 of 5 John Hancock fundsFor—
DYNE THERAPEUTICS, INC.2026-06-05To elect three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified. David LubnerForWITHHOLD — 3 of 5 John Hancock fundsFor—
DYNE THERAPEUTICS, INC.2026-06-05To elect three Class III directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified. Jason RhodesForWITHHOLD — 3 of 5 John Hancock fundsFor—
APOGEE THERAPEUTICS, INC.2026-06-09DIRECTOR: William (BJ) Jones, Jr.ForABSTAIN — 3 of 5 John Hancock fundsFor—
AURORA INNOVATION, INC.2026-05-21Election of Directors Michelangelo VolpiForWITHHOLD — 2 of 3 John Hancock fundsFor—

Download all 34 differences (CSV)

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 93.7% of this fund’s 687 such votes could be given a sector; the other 43 (6.3%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Technology1813418.8%
Health Care13732.2%
Consumer Discretionary1062018.9%
Finance6369.5%
Utilities5400.0%
Energy4648.7%
Industrials4012.5%
Consumer Staples1200.0%
Telecommunications500.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections4731
Audit-related550
Say-on-Pay541
Corporate Governance2815
Other Social Issues2020
Human Rights or Human Capital/workforce1616
Capital Structure120
Compensation121
Environment or Climate77
Shareholder Rights and Defenses64

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
MICROSOFT CORPORATIONDecember 5, 2025$28M216
AMAZON.COM, INC.May 20, 2026$27M174
APPLE INC.February 24, 2026$26M121
META PLATFORMS, INC.May 27, 2026$20M2310
ADVANCED MICRO DEVICES, INC.May 13, 2026$18M121
REVVITY, INC.April 28, 2026$16M141
BECTON, DICKINSON AND COMPANYJanuary 27, 2026$14M160
NVIDIA CORPORATIONJune 24, 2026$13M164

Notable votes against management

MeetingCompanyProposalFundMgmt
December 5, 2025MICROSOFT CORPORATIONEuropean Security Program Censorship Risk Audit Shareholder proposalAgainstFor
December 5, 2025MICROSOFT CORPORATIONReport on Risks of Censorship in Generative Artificial Intelligence Shareholder proposalAgainstFor
May 20, 2026AMAZON.COM, INC.SHAREHOLDER PROPOSAL REQUESTING A REPORT ON CHARITABLE PARTNERSHIPS Shareholder proposalAgainstFor
May 20, 2026AMAZON.COM, INC.SHAREHOLDER PROPOSAL REQUESTING ADDITIONAL REPORTING ON IMPACT OF DATA CENTERS ON CLIMATE COMMITMENTS Shareholder proposalAgainstFor
February 24, 2026APPLE INC.A shareholder proposal entitled "China Entanglement Audit" Shareholder proposalAgainstFor
May 27, 2026META PLATFORMS, INC.A shareholder proposal regarding report on Al data usage oversight. Shareholder proposalForAgainst
May 27, 2026META PLATFORMS, INC.A shareholder proposal regarding annual vote regarding executive pay. Shareholder proposalForAgainst
May 13, 2026ADVANCED MICRO DEVICES, INC.Stockholder proposal requesting changes to the stockholder right to call a special meeting. Shareholder proposalAgainstFor
April 28, 2026REVVITY, INC.To approve the shareholder proposal regarding Executives to Retain Significant Stock. Shareholder proposalAgainstFor
June 24, 2026NVIDIA CORPORATIONApproval of a non-binding stockholder proposal requesting the replacement of supermajority voting provisions in our charter and bylaws with a simple majority voting standard. Shareholder proposalForAgainst
June 24, 2026NVIDIA CORPORATIONApproval of a non-binding stockholder proposal requesting a report on faith-based community resource groups. Shareholder proposalAgainstFor
June 5, 2026ALPHABET INC.Shareholder proposal regarding an enhanced disclosure on climate goals Shareholder proposalAgainstFor

Funds that vote the same way

These funds reported the same votes as Capital Appreciation Value Trust in the latest season, so they share this page:

Search this fund’s votes by company

689 ballot items at 56 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Capital Appreciation Value Trust (JAFPX) voted at 56 shareholder meetings of 56 companies, on 689 ballot items in all. Where management made a recommendation, the fund followed it on 88.8% of the items and voted against it 68 times. Its most frequent area of disagreement was other social issues (20 of its votes against management). It voted FOR 13.0% of the 69 shareholder proposals on which it cast a FOR or AGAINST vote. It voted FOR the board's own proposals more often than John Hancock's funds as a whole (95.7% against 90.1%). It voted differently from most John Hancock funds on 34 items.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of John Hancock’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.